High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. - Wikidata - awgldk - TriplyDB

High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management.

High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management.

http://www.wikidata.org/entity/Q33747348

about

Current perspectives on desmoid tumors: the mayo clinic approach CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.Adult desmoid tumors: biology, management and ongoing trials.Desmoid tumors: clinical features and treatment options for advanced disease Isolated limb perfusion using tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis.Optimal therapy for desmoid tumors: current options and challenges for the future.Prediction of desmoid tumor progression using miRNA expression profiling Tailored Beta-catenin mutational approach in extra-abdominal sporadic desmoid tumor patients without therapeutic intervention.Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study.Characteristics of cultured desmoid cells with different CTNNB1 mutation status.Clinical significance of midkine expression in sporadic desmoid tumors Simple resection of truncal desmoid tumors: A case series β-Catenin mutation status and outcomes in sporadic desmoid tumors.Pancreatic solitary fibrous tumor in a toddler managed by pancreaticoduodenectomy: a case report and review of the literature.Gastrointestinal Mesenchymal Neoplasms other than Gastrointestinal Stromal Tumors: Focusing on Their Molecular Aspects.Fibroblastic tumors of intermediate malignancy in childhood.Surgical outcomes following resection for sporadic abdominal wall fibromatosis.Intra-abdominal desmoid tumor after liver transplantation: A case report.Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).Desmoid Tumors: A Review of the Literature and Pharmacologic Management.Human microRNA expression in sporadic and FAP-associated desmoid tumors and correlation with beta-catenin mutations.β-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis.A 13 kg intra-abdominal mass: a case of mesenteric fibromatosis.Effect of surgical margins on prognosis in aggressive fibromatosis: A single-institutional analysis of 90 patients.β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression.An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (ST CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study.The treatment of desmoid tumors: a stepwise clinical approach.CTNNB1 genotyping and APC screening in pediatric desmoid tumors: a proposed algorithm.Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01).Intra-Abdominal and Abdominal Wall Desmoid Fibromatosis.Proof of concept: prognostic value of the plasmatic concentration of circulating cell free DNA in desmoid tumors using ddPCR.Orbital Desmoid-Type Fibromatosis: A Case Report and Literature Review.‘Difficult to diagnose’ desmoid tumours: a potential role forCTNNB1mutational analysis

P2860

Q30355420-3B1B442E-21C2-468A-913A-FC3E542D7A8F Q33553463-CA967A90-38D7-46A5-93A1-F595AFCFA444 Q33797947-49C0DAE3-89AF-410D-9A2D-E4DBC3E901C5 Q34628337-4D5D79D7-E2F1-42F3-8D30-B266E75BD109 Q34665261-25A80532-8813-44FE-B590-365284B72EC4 Q34674007-07A5E045-4F19-43C8-8D43-982B9DBF950C Q35674236-591280DE-E976-4642-BE3E-5E99CFF246B1 Q36114566-FCBEBB2B-2880-46D6-9B2E-C6662AC2B1A0 Q36283018-12A1EB5B-51A1-4C0B-A285-7B0F36FE0797 Q36528428-FB468075-9101-4A68-A31A-D6F4831F80B5 Q36640207-B2BAADC6-D9B3-4624-AB83-EAB29DE15060 Q37107708-3B791434-D228-4F86-810B-5AEFB9CC5A27 Q37191340-B7999395-A134-4DFA-B36A-76810E126555 Q37733261-A7EDCA0C-1AFD-4C17-9661-35C9F8EAC51F Q37853030-D5F58467-4742-4697-A413-F216FE003C82 Q38081247-9D5361C5-08D9-4D33-B09D-8082A4140B30 Q38194092-D5633A26-07E3-4B0A-A4D9-8307E9B741E0 Q38230453-0F3907C5-13CE-498D-81ED-449D65850F36 Q38375349-76EC161B-C9B3-4D98-AC7A-9671BEDA5892 Q38829642-037A8E6F-C281-400C-9603-1C4E64946BD0 Q41091778-AA5B3B0A-6113-4D46-BEB9-2F1D56835339 Q43503416-12D4C42C-C9B7-4247-9D85-FC12330F39B5 Q43533123-9ECE572B-0F82-425A-A3C4-9B27D4690CA2 Q45543441-FEC97B2A-16C5-47F5-962E-18221AD5B57D Q47106275-FC279576-8A05-40BF-BFAE-11EF5540E691 Q47666781-C2BF43A7-1B20-4F21-91F1-F959FA60CF28 Q47862484-D3980EB7-4456-43B2-9728-D56F05F6D514 Q50122182-ACCB7C9D-BB8D-4B4B-8A63-FE3576C6B85D Q51413671-E3E3100B-8AB7-4A41-BBE0-1D601BB064DD Q52856710-596C2C52-0723-4EA4-9D44-9319355B4C04 Q55052699-A8105837-D392-4790-941C-776FB80064F9 Q55115149-64808A90-D0D2-4B07-85A6-02ADEEFD68B7 Q55127875-C23A9A38-85F7-4C11-AA3F-04953858688D Q57741160-05B57007-72B7-4573-9CEE-C72B5ED37440

P2860

High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management.

http://www.wikidata.org/entity/Q33747348

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

High frequency of beta-catenin ...... r tool for disease management.

@ast

High frequency of beta-catenin ...... r tool for disease management.

@en

type

label

High frequency of beta-catenin ...... r tool for disease management.

@ast

High frequency of beta-catenin ...... r tool for disease management.

@en

prefLabel

High frequency of beta-catenin ...... r tool for disease management.

@ast

High frequency of beta-catenin ...... r tool for disease management.

@en

P1433

Q33747348-A6BD863E-DEFF-4CE5-A463-CD61FB6A0C57

P1476

Q33747348-A93E0D2B-AE0D-48EC-9CDF-A15B9B764AC7

P2093

Q33747348-125B9E7D-3BCD-48F7-B0BF-59726AF9ADD4

Q33747348-1AD48E2B-44E2-434E-9DFE-8F46C664D263

Q33747348-1D9740EB-E6D4-4C65-BBEA-F0BD9BE41794

Q33747348-2EF71EB4-0C17-451A-9F57-36701BA416E0

Q33747348-387E5581-4FD6-4674-9111-031FE64F3227

Q33747348-5EB89399-7C40-4B24-8D08-DF98A24731B3

Q33747348-72332DA7-B5AC-4453-9108-B293A730314E

Q33747348-B8951CA6-C89C-47A9-B0F5-3064EDE8D1A1

Q33747348-BF99140A-E778-45EF-B803-611F3748199A

Q33747348-C117493F-FAF2-4050-9146-471CE58FA6F2

P2860

Q33747348-08FF1A9C-1939-442E-9298-CF86E35BC2D9

Q33747348-091A84BF-4884-460B-B65D-B4C7338B4B00

Q33747348-117772C4-FA00-48EA-9F78-1214516888E5

Q33747348-2C92A7EC-1E68-49F5-866A-0F156764F596

Q33747348-4071AC8F-5B6B-4A54-BC48-5624EEEC4318

Q33747348-46203CEE-457F-4483-92CB-F1A278D9CAD8

Q33747348-4F3A996C-C6A3-4F8C-A58C-A100D4D73EFC

Q33747348-859558A9-3989-45E5-8737-9547DD641A7B

Q33747348-98F64090-474D-4E7D-B35D-2D3752CB9DC2

Q33747348-D03EE3F5-6F4D-407D-979A-C34DAB48626C

P2888

Q33747348-D209D67F-809C-4FE0-AE69-C6E5C797ADA9

P304

Q33747348-EE5FF374-1569-4C10-BA74-46CCAAD7F76C

P31

Q33747348-E8367D15-2914-4A69-A418-70041808B22F

P356

Q33747348-07D5B8E6-E5CB-4937-95DD-7C56C16812E2

P407

Q33747348-915E53BD-98CF-4288-AF8A-0D13052F96FF

P433

Q33747348-DD8EB42D-3B95-41A0-8ECD-8C97DAA3BD22

P478

Q33747348-EAE82BAB-615E-4433-A117-8DA82EFC9F1F

P50

Q33747348-75C25FF4-1DEA-471B-B841-FFDE4E549E15

Q33747348-93DB11AF-42C5-4904-A40D-422C4E56ABB2

P577

Q33747348-07971C8E-7E2C-4A5F-ADD7-443C475583A3

P5875

Q33747348-AE58FEAD-F27D-4581-A06E-8702703B94A7

P6179

Q33747348-AABBBC36-F572-48D1-9580-C58A291B02F9

P698

Q33747348-DE7F93F4-7731-46A4-8D4F-A917894B9A03

P932

Q33747348-E77C8981-B1B5-488A-B33E-55831B3F4FC0

P356

P1433

British Journal of Cancer

P1476

High frequency of beta-catenin ...... r tool for disease management.

@en

P2093

A Dufresne

http://www.w3.org/2001/XMLSchema#string

A Leroux

http://www.w3.org/2001/XMLSchema#string

A Neuville

http://www.w3.org/2001/XMLSchema#string

D Ranchère

http://www.w3.org/2001/XMLSchema#string

F Collin

http://www.w3.org/2001/XMLSchema#string

J Bénard

http://www.w3.org/2001/XMLSchema#string

J Dômont

http://www.w3.org/2001/XMLSchema#string

J-M Coindre

http://www.w3.org/2001/XMLSchema#string

L Guillou

http://www.w3.org/2001/XMLSchema#string

L Lacroix

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC

Wnt/beta-catenin signaling in development and disease

Mechanistic insights from structural studies of beta-catenin and its binding partners

beta-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds

Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors.

Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development.

The many ways of Wnt in cancer.

Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors).

Loss of beta-catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene.

Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment.

P2888

P304

1032-1036

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605557

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41669592

http://www.w3.org/2001/XMLSchema#string

P6179

1046435677

http://www.w3.org/2001/XMLSchema#string

P698

20197769

http://www.w3.org/2001/XMLSchema#string

P932

2844024

http://www.w3.org/2001/XMLSchema#string